Lucentis

eye doctor opthalmology phoropter glasses eye disease vision
Biotech

Outlook's eye disease drug fails to match Lucentis, sinking stock

The biotech brushed off the failure, noting positive details and vowing to seek FDA approval, but investors were less sanguine about the setback.
Nick Paul Taylor Nov 27, 2024 8:40am
eyes

ProQR nabs former Lucentis developer as new CSO

Oct 5, 2020 8:25am
eye

Opthea's VEGF 'trap' combo bests Lucentis alone in wet AMD

Sep 6, 2019 11:24am
eye

Genentech’s first drug implant clears phase 2 study in wet AMD

Jul 26, 2018 2:30pm
Crater

Ophthotech completes clean sweep of phase 3 trial flops

Aug 14, 2017 9:00am
Blue eye

Novartis' longer-acting AMD drug matches Eylea in phase 3 trials

Jun 20, 2017 7:39am